2022年8月18日-19日，由Taas Labs谈思生物主办的“核酸汇·2022中国核酸药物与新型疫苗产业大会”在中国武汉隆重召开。博沃生物项目经理徐龙博士作为重要嘉宾出席大会并就“国内外疫苗研发技术与进展”主题发表演讲“广谱新冠疫苗的研发策略”。
On August 18-19th, the "2022 China Nucleic Acid Drug and Neotype Vaccine Industrial Conference" was successfully held by Taas Labs in Wuhan, China. Dr. Xu Long, Project Manager of BravoBio, attended the Conference and gave a keynote speech on "Development Strategy of a Novel Broad-Spectrum Coronavirus Vaccine" under "Domestic and International Vaccine Research and Development Progress".
本次大会专注核酸药物与新型疫苗领域，整合了国内外及全产业优质资源，以专业视角，发展眼光，把握产业风向，掀起一场“思想风暴”。会议上，徐龙博士对现有新冠疫苗的研发状况做了总结性概述，并提出开发广谱新冠疫苗的必要性。从疫苗技术路线、行业发展视角等方面进行分析，提出开发广谱新冠疫苗的新策略。徐龙博士表示，虽然目前开发广谱新冠疫苗还存在诸多挑战，但随着合作商业化、产业链上下游实现快速发展，我们有望实现广谱冠状病毒疫苗的快速上市，真正终结新冠疫情。
Focusing on the domains of nucleic acid drug and novel vaccine, the Conference integrated high-level resources in China and worldwide, and provided "ideological storms" by seizing the industry vane from professional and evolutionary perspectives. In the Conference, Dr. Xu gave an overview of the current R&D of COVID-19 vaccines, and expressed the necessity and urgency of developing a broad-spectrum coronavirus vaccine. Dr. Xu said, "though there are still major obstacles to developing a broad-spectrum coronavirus vaccine at this moment, with the commercialization of further cooperation and rapid development of upstream and downstream of the industrial chain, we are in the hope that a broad-spectrum coronavirus vaccine will be launched on the market in the near future and ultimately put an end to the COVID-19 pandemic."
By the time of this press release, the construction of the headquarter base had already begun to take shape.
关于博沃生物
上海博沃生物科技有限公司（简称博沃生物）2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤Deloitte评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a “state level high-tech enterprise” and a council member of China Association of Vaccines (CAV). It was awarded as “China Rising Star” by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing/onstruction/cloning/detection, large-scale bacterial/cell/virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people’s lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注我们
长按二维码 关注我们
公司官网｜www.bravobio.com